Relevant concomitant care permitted or prohibited during the
trial
Treatment with any or all of the following therapies is permitted during
the study and not a reason to withhold study medication: deep vein
thrombosis prophylaxis with UFH or low molecular weight heparin (LMWH);
‘full’ therapeutic dose UFH or LMWH for a recognised clinical
indication; non-heparin anticoagulants; anti-thrombotic medications;
protamine; prone positioning; and inhaled nitric oxide. There are no
prohibitions during the trial.